SG11201811202WA - Human liver chimeric non-human animal with deficient p450 oxidoreductase and methods of using same - Google Patents
Human liver chimeric non-human animal with deficient p450 oxidoreductase and methods of using sameInfo
- Publication number
- SG11201811202WA SG11201811202WA SG11201811202WA SG11201811202WA SG11201811202WA SG 11201811202W A SG11201811202W A SG 11201811202WA SG 11201811202W A SG11201811202W A SG 11201811202WA SG 11201811202W A SG11201811202W A SG 11201811202WA SG 11201811202W A SG11201811202W A SG 11201811202WA
- Authority
- SG
- Singapore
- Prior art keywords
- human
- international
- chimeric non
- methods
- type
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 210000004185 liver Anatomy 0.000 title abstract 3
- 102000004316 Oxidoreductases Human genes 0.000 title abstract 2
- 108090000854 Oxidoreductases Proteins 0.000 title abstract 2
- 230000002950 deficient Effects 0.000 title abstract 2
- 238000012217 deletion Methods 0.000 abstract 4
- 230000037430 deletion Effects 0.000 abstract 4
- 210000003494 hepatocyte Anatomy 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 108091033409 CRISPR Proteins 0.000 abstract 1
- 101100193633 Danio rerio rag2 gene Proteins 0.000 abstract 1
- 108020005004 Guide RNA Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 101100193635 Mus musculus Rag2 gene Proteins 0.000 abstract 1
- 210000001671 embryonic stem cell Anatomy 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 101150067427 por gene Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 229940126586 small molecule drug Drugs 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
- C12N9/0038—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
- C12N9/0042—NADPH-cytochrome P450 reductase (1.6.2.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01022—UDP-glucose 6-dehydrogenase (1.1.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
- C12Y106/02—Oxidoreductases acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
- C12Y106/02004—NADPH-hemoprotein reductase (1.6.2.4), i.e. NADP-cytochrome P450-reductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
- C12Y603/02003—Glutathione synthase (6.3.2.3)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 1110101011111 011101 0 01111111100111111H1101111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2018/005471 Al 04 January 2018 (04.01.2018) W I PO I PCT (51) International Patent Classification: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, AO1K 67/027 (2006.01) A01K 67/02 (2006.01) KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2017/039474 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (22) International Filing Date: TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 27 June 2017 (27.06.2017) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 62/355,102 27 June 2016 (27.06.2016) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 62/509,942 23 May 2017 (23.05.2017) US MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (71) Applicant: BAYLOR COLLEGE OF MEDICINE KM, ML, MR, NE, SN, TD, TG). [US/US]; 1 Baylor Plaza, Houston, Texas 77030 (US). (72) Inventor: BISSIG, Karl-Dimiter; c/o Baylor College of Published: Medicine, 1 Baylor Plaza, Houston, Texas 77030 (US). — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (74) Agent: PAVAO, Matthew et al.; Cooley LLP, 1299 Penn- _ sylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US). — = Designated States (unless otherwise indicated, for every (81) kind of national protection available): AE, AG, AL, AM, = _ AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, _ = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, Title: HUMAN LIVER CHIMERIC NON-HUMAN ANIMAL WITH DEFICIENT P450 OXIDOREDUCTASE AND (54) METHODS OF USING SAME (57) : The present disclosure provides a chimeric non-human animal com- prising human hepatocytes, methods for preparing the chimeric non-human animal = Figure 1A comprising human hepatocytes and methods of utilizing the chimeric non-human an- = = PIRF mouse strain imal comprising human hepatocytes to screening and identifying metabolites for any Por gene . LoxP Low type of drugs, typically small molecule drugs, which might affect human liver func- = _ Wild-type E5 E6 all-tions and any other bodily function. Lo re Conditional E7 = = deletion = 112-rg gene s 2300bp = Wild-type GI Mill-13- 131-31 IM = Deletion -E -131-11:1- Rag2 gene5 850bp li Wild -type El .4 \/ PSI Deletion == I E1 I IN 71' in 1700bp Fah gene5 Wild type - - M - EI - 1:11/ IM - 2I IF © © ,-.... Deletion - 01 - 131 - 21 . MM 1211 -- 1-1 0 N 'Embryonic stem cell targeting (See, Figure 4) A .,,,, § Zygote injection with Cas9 and gRNA (See, Figure 5)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662355102P | 2016-06-27 | 2016-06-27 | |
US201762509942P | 2017-05-23 | 2017-05-23 | |
PCT/US2017/039474 WO2018005471A1 (en) | 2016-06-27 | 2017-06-27 | Human liver chimeric non-human animal with deficient p450 oxidoreductase and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811202WA true SG11201811202WA (en) | 2019-01-30 |
Family
ID=59351074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811202WA SG11201811202WA (en) | 2016-06-27 | 2017-06-27 | Human liver chimeric non-human animal with deficient p450 oxidoreductase and methods of using same |
Country Status (12)
Country | Link |
---|---|
US (2) | US11716974B2 (en) |
EP (1) | EP3474662A1 (en) |
JP (2) | JP2019524077A (en) |
KR (1) | KR102466092B1 (en) |
CN (2) | CN114875066A (en) |
AU (1) | AU2017289194B2 (en) |
CA (1) | CA3027752A1 (en) |
IL (1) | IL263693B2 (en) |
MX (1) | MX2018016307A (en) |
SG (1) | SG11201811202WA (en) |
TW (1) | TWI767916B (en) |
WO (1) | WO2018005471A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113440502B (en) * | 2020-11-30 | 2022-10-18 | 先见明创医药科技(苏州)有限公司 | Programmed chronic liver injury maintenance of Fah gene-deficient animals and application of programmed chronic liver injury maintenance in preparation of heterogeneous liver model |
CN114717195A (en) * | 2022-04-29 | 2022-07-08 | 武汉大学 | Cell model for screening exogenous compounds mediated by CYP3A7 and metabolized to toxicity, construction method and application thereof |
WO2024020057A1 (en) * | 2022-07-19 | 2024-01-25 | Regeneron Pharmaceuticals, Inc. | Genetically modified animal model and its use to model the human immune system |
CN115851640A (en) * | 2022-12-30 | 2023-03-28 | 天津大学 | Module for avoiding path competition by mixed bacteria and application thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6509514B1 (en) | 2000-03-17 | 2003-01-21 | Kmt Hepatech, Inc. | Chimeric animal model susceptible to human hepatitis C virus infection |
US7700822B2 (en) * | 2002-07-12 | 2010-04-20 | Cancer Research Technology Limited | Modulation of cytochrome P450 reductase activity |
GB0216203D0 (en) | 2002-07-12 | 2002-08-21 | Imp Cancer Res Tech | Mondulation of cytochrome P450 reductase activity |
JPWO2004032615A1 (en) | 2002-10-11 | 2006-02-02 | 独立行政法人産業技術総合研究所 | Bradion gene expression-suppressed chimeric mice |
GB0402318D0 (en) | 2004-02-03 | 2004-03-10 | Imp Cancer Res Tech | Transgenic animals for assessing drug metabolism and toxicity in man |
US7759541B2 (en) | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
JP5497639B2 (en) * | 2007-06-05 | 2014-05-21 | オレゴン ヘルス アンド サイエンス ユニバーシティ | Method for expanding human hepatocytes in vivo |
GB0718029D0 (en) | 2007-09-14 | 2007-10-24 | Iti Scotland Ltd | Two step cluster deletion and humanisation |
GB0720552D0 (en) | 2007-10-19 | 2007-11-28 | Iti Scotland Ltd | Multiple cluster knockout |
CA2760608A1 (en) | 2009-05-01 | 2010-11-04 | Oregon Health & Science University | Method of expanding human hepatocytes in vivo |
WO2012029784A1 (en) | 2010-08-31 | 2012-03-08 | 国立大学法人熊本大学 | Method of establishing mouse strain |
JP6484444B2 (en) * | 2011-08-26 | 2019-03-13 | イエキュリス コーポレーションYecuris Corporation | Fumaryl acetoacetate hydrolase (FAH) deficient and immunodeficient rats and their use |
JP5883265B2 (en) | 2011-10-13 | 2016-03-09 | 株式会社フェニックスバイオ | Chimeric non-human animals carrying human hepatocytes |
JP5976380B2 (en) | 2012-04-27 | 2016-08-23 | 公益財団法人東京都医学総合研究所 | Urokinase-type plasminogen activator transgenic mouse |
WO2013188522A2 (en) | 2012-06-12 | 2013-12-19 | Genentech, Inc. | Methods and compositions for generating conditional knock-out alleles |
-
2017
- 2017-06-27 JP JP2018567651A patent/JP2019524077A/en not_active Withdrawn
- 2017-06-27 WO PCT/US2017/039474 patent/WO2018005471A1/en unknown
- 2017-06-27 MX MX2018016307A patent/MX2018016307A/en unknown
- 2017-06-27 CN CN202210513465.1A patent/CN114875066A/en active Pending
- 2017-06-27 IL IL263693A patent/IL263693B2/en unknown
- 2017-06-27 AU AU2017289194A patent/AU2017289194B2/en active Active
- 2017-06-27 TW TW106121484A patent/TWI767916B/en active
- 2017-06-27 CN CN201780052153.2A patent/CN109688810B/en active Active
- 2017-06-27 EP EP17740168.4A patent/EP3474662A1/en active Pending
- 2017-06-27 KR KR1020197002668A patent/KR102466092B1/en active IP Right Grant
- 2017-06-27 US US16/309,871 patent/US11716974B2/en active Active
- 2017-06-27 SG SG11201811202WA patent/SG11201811202WA/en unknown
- 2017-06-27 CA CA3027752A patent/CA3027752A1/en active Pending
-
2022
- 2022-02-07 JP JP2022017030A patent/JP2022065020A/en active Pending
-
2023
- 2023-06-15 US US18/335,959 patent/US20230337643A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL263693B1 (en) | 2023-11-01 |
TWI767916B (en) | 2022-06-21 |
JP2022065020A (en) | 2022-04-26 |
AU2017289194A1 (en) | 2019-01-17 |
IL263693B2 (en) | 2024-03-01 |
US20190166810A1 (en) | 2019-06-06 |
EP3474662A1 (en) | 2019-05-01 |
MX2018016307A (en) | 2019-05-20 |
CA3027752A1 (en) | 2018-01-04 |
WO2018005471A1 (en) | 2018-01-04 |
US20230337643A1 (en) | 2023-10-26 |
IL263693A (en) | 2019-01-31 |
TW201803988A (en) | 2018-02-01 |
CN109688810B (en) | 2022-06-03 |
JP2019524077A (en) | 2019-09-05 |
CN114875066A (en) | 2022-08-09 |
CN109688810A (en) | 2019-04-26 |
US11716974B2 (en) | 2023-08-08 |
KR102466092B1 (en) | 2022-11-11 |
KR20190022799A (en) | 2019-03-06 |
AU2017289194B2 (en) | 2019-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201811202WA (en) | Human liver chimeric non-human animal with deficient p450 oxidoreductase and methods of using same | |
SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
SG11201810757YA (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
SG11201903480TA (en) | Cell culture device system and methods of use thereof | |
SG11201407370QA (en) | Humanized il-7 rodents | |
SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
SG11201804375WA (en) | Compositions and methods for internalizing enzymes | |
SG11201907870VA (en) | Compositions and methods for inhibition of lineage specific proteins | |
SG11201805532XA (en) | Multivalent and multispecific 41bb-binding fusion proteins | |
SG11201807279QA (en) | Binding proteins and methods of use thereof | |
SG11201811405QA (en) | Improved differentiation method | |
SG11201810003UA (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
SG11201909160WA (en) | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same | |
SG11201811193TA (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
SG11201805835WA (en) | Modified oncolytic virus | |
SG11201910096RA (en) | Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201406903SA (en) | Cell culture compositions and methods for polypeptide production | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201908127WA (en) | Method for producing multispecific antibodies | |
SG11201909303TA (en) | Point of delivery cold slurry generation | |
SG11201807881VA (en) | Compositions and methods for making antibodies based on use of an expression-enhancing locus | |
SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
SG11201907685TA (en) | Compositions and methods for robust dynamic metabolic control |